Neurocrine's CRENESSITY launch accelerates as Q2 revenue jumps 39%
CRENESSITY data broadens and launch surges New ENDO 2026 data showed CRENESSITY improved hormone control, heart and bone health in CAH, and Q2 sales then jumped 247% to $184 million. This tells investors the newest drug is becoming a real second growth engine, not just a promise.
It is the core new growth story behind the stock's move.
Q2 results beat and INGREZZA guidance raised Second-quarter revenue rose 39% to $959 million and adjusted earnings jumped to $2.85 a share. Management raised full-year INGREZZA sales guidance to $2.825-$2.875 billion, signaling the flagship drug keeps growing faster than expected.
The earnings beat and raised guidance are the period's biggest fresh price driver.
Crinecerfont expands toward younger children Neurocrine started a Phase 2 trial of crinecerfont in children aged 3 months to under 4, aiming to widen CRENESSITY's approved use. A larger patient pool means more future sales, though approval is still years away.
It is a new pipeline expansion that supports long-term growth expectations.
Analyst estimates and valuation draw buyers Analysts raised earnings estimates sharply, earning a Zacks Strong Buy, while the stock trades near 17 times forward earnings versus an industry average above 90. Cheap valuation plus rising estimates makes the shares attractive to new investors.
It explains the money-flow and sentiment side of the rally.